Dr Graffner will oversee the clinical development programs at Albireo with initial focus on the lead program A3309, a therapeutic with a novel mechanism of action targeting the treatment of patients with chronic constipation.
Most recently, Dr Graffner was the senior medical director at Merck Serono, leading clinical development of products mainly in the areas of autoimmune diseases, including inflammatory bowel diseases.